Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selicrelumab + Atezolizumab in Advanced Solid Tumors
NCT02304393Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of selicrelumab in solid tumor, colorectal cancer (CRC), small intestine cancer and 2 more (4 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events and Serious Adverse Events, Percentage of Participants With Dose-Limiting Toxicities and 7 more. Started Dec 2014; status: completed.
02
Drugs
selicrelumab
03
Conditions
solid tumorcolorectal cancer (CRC)small intestine cancernon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02304393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304393.